The cost utility of bisphosphonate treatment in established osteoporosis

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis in Iran

Background: Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at a high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is estimating the cost-utility of Teriparatide compared with no treatment from health system perspective in Iran. Method: A microsimulation...

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis in Iran

Background: Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at a high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is estimating the cost-utility of Teriparatide compared with no treatment from health system perspective in Iran. Method: A microsimulation...

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

Breaking Point The economic cost of not adhering to bisphosphonate treatment for osteoporosis

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

BACKGROUND The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in Spain. METHODS A Markov model represented the possible health state transitions of Spanish postmenopausal women from initiation of fracture prevention t...